Outlook Therapeutics announces NICE recommendation of LYTENAVA

Outlook Therapeutics (OTLK) announced that the National Institute for Health and Care Excellence, NICE, has recommended LYTENAVA, as an option for the treatment of wet AMD. LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and UK and has an initial 10 years of market exclusivity. “We are very pleased to receive the NICE recommendation of LYTENAVA(TM) (bevacizumab gamma) for patients with wet AMD. As the first positive reimbursement decision worldwide, this builds on our momentum and bolsters our commercialization strategy moving forward,” commented Jedd Comiskey, Senior Vice President, Head of Europe, of Outlook Therapeutics. “We remain committed to providing the UK health system with a cost effective treatment option for treating wet AMD. Looking ahead, our team continues preparations for commercial launch in the UK anticipated in 2025 and continues to work through the pricing and reimbursement processes for EU countries, with launches in the EU anticipated to follow.”